Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07323329
PHASE2/PHASE3

Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

Sponsor: Beni-Suef University

View on ClinicalTrials.gov

Summary

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Official title: Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization

Key Details

Gender

FEMALE

Age Range

18 Years - 35 Years

Study Type

INTERVENTIONAL

Enrollment

165

Start Date

2025-10-10

Completion Date

2026-11-12

Last Updated

2026-01-07

Healthy Volunteers

No

Interventions

DRUG

Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.

Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.

DRUG

DHEA plus folic acid 400mcg per day

Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day

DIETARY_SUPPLEMENT

control group

Patients will receive folic acid 400 mcg per day

Locations (1)

Beni-Suef University Hospital

Banī Suwayf, Beni Suweif Governorate, Egypt